within Pharmacolibrary.Drugs.ATC.J;

model J05AR25
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 1.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 350 / 1000000,
    adminCount     = 1,
    Vd             = 0.0178,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.022000000000000002,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Lamivudine and dolutegravir is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), while dolutegravir is an integrase strand transfer inhibitor (INSTI). This combination is approved and widely used as a once-daily regimen in adults and adolescents for HIV therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects receiving oral administration of the fixed dose combination (lamivudine 300 mg, dolutegravir 50 mg) as a single dose.</p><h4>References</h4><ol><li><p>Singh, RP, et al., &amp; Wynne, B (2021). Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. <i>Clinical pharmacology in drug development</i> 10(9) 985–993. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.996&quot;>10.1002/cpdd.996</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34265164/&quot;>https://pubmed.ncbi.nlm.nih.gov/34265164</a></p></li><li><p>Dumitrescu, TP, et al., &amp; Adkison, K (2020). Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine. <i>Clinical pharmacology in drug development</i> 9(2) 189–202. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.740&quot;>10.1002/cpdd.740</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31724343/&quot;>https://pubmed.ncbi.nlm.nih.gov/31724343</a></p></li><li><p>Singh, RP, et al., &amp; Buchanan, AM (2022). Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children. <i>The Pediatric infectious disease journal</i> 41(3) 230–237. DOI:<a href=&quot;https://doi.org/10.1097/INF.0000000000003366&quot;>10.1097/INF.0000000000003366</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34817414/&quot;>https://pubmed.ncbi.nlm.nih.gov/34817414</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AR25;
